{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T06:22:43Z","timestamp":1795155763492,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00259-024-06813-8","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:02:42Z","timestamp":1719212562000},"page":"3744-3752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma"],"prefix":"10.1007","volume":"51","author":[{"given":"Kurt T.","family":"Pianka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Barahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeet","family":"Minocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas W.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Schnickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-9772","authenticated-orcid":false,"given":"Zachary T.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"issue":"7","key":"6813_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557\u201376. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.061.","journal-title":"Gastroenterology"},{"issue":"1","key":"6813_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"8","key":"6813_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1478-3231.2011.02473.x","volume":"31","author":"M Fujiki","year":"2011","unstructured":"Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int. 2011;31(8):1081\u20139. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02473.x.","journal-title":"Liver Int"},{"issue":"4","key":"6813_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","volume":"271","author":"J DiNorcia","year":"2020","unstructured":"DiNorcia J, Florman SS, Haydel B, et al. Pathologic response to Pretransplant Locoregional Therapy is predictive of patient Outcome after Liver Transplantation for Hepatocellular Carcinoma: analysis from the US Multicenter HCC Transplant Consortium. Ann Surg. 2020;271(4):616. https:\/\/doi.org\/10.1097\/SLA.0000000000003253.","journal-title":"Ann Surg"},{"issue":"12","key":"6813_CR5","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1097\/01.TP.0000145892.97114.EE","volume":"78","author":"M Ravaioli","year":"2004","unstructured":"Ravaioli M, Grazi GL, Ercolani G, et al. Partial necrosis on Hepatocellular Carcinoma Nodules Facilitates Tumor Recurrence after liver transplantation. Transplantation. 2004;78(12):1780. https:\/\/doi.org\/10.1097\/01.TP.0000145892.97114.EE.","journal-title":"Transplantation"},{"issue":"3","key":"6813_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.31318","volume":"73","author":"A Gabr","year":"2021","unstructured":"Gabr A, Kulik L, Mouli S, et al. Liver transplantation following Yttrium-90 radioembolization: 15\u2010Year experience in 207\u2010Patient cohort. Hepatology. 2021;73(3):998. https:\/\/doi.org\/10.1002\/hep.31318.","journal-title":"Hepatology"},{"issue":"5","key":"6813_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the Treatment of Solitary, Unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"issue":"2","key":"6813_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580\u20133. https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6813_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","volume":"32","author":"B Toskich","year":"2021","unstructured":"Toskich B, Vidal LL, Olson MT, et al. Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: a validation study. J Vasc Interv Radiol. 2021;32(4):518\u2013e5261. https:\/\/doi.org\/10.1016\/j.jvir.2020.12.019.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"6813_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","volume":"79","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B, et al. Radiation Segmentectomy: a Novel Approach to increase Safety and Efficacy of Radioembolization. Int J Radiation Oncology*Biology*Physics. 2011;79(1):163\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.062.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"1","key":"6813_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatology"},{"issue":"9","key":"6813_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7(9):843\u201350. https:\/\/doi.org\/10.1016\/S2468-1253(22)00091-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"6813_CR13","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49(11):3892\u20137. https:\/\/doi.org\/10.1007\/s00259-022-05776-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6813_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semradonc.2019.08.005","volume":"30","author":"JK Mikell","year":"2020","unstructured":"Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and hepatic metastases: clinical aspects and Dosimetry models. Semin Radiat Oncol. 2020;30(1):68. https:\/\/doi.org\/10.1016\/j.semradonc.2019.08.005.","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"6813_CR15","first-page":"1209","volume":"47","author":"SA Gulec","year":"2006","unstructured":"Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-Microsphere therapy of Liver Cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209\u201311.","journal-title":"J Nucl Med"},{"issue":"10","key":"6813_CR16","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1002\/mp.14452","volume":"47","author":"MA Thomas","year":"2020","unstructured":"Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for 90Y radioembolization with glass microspheres: evaluating the fidelity of 99mTc-MAA and partition model predictions. Med Phys. 2020;47(10):5333\u201342. https:\/\/doi.org\/10.1002\/mp.14452.","journal-title":"Med Phys"},{"issue":"9","key":"6813_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","volume":"51","author":"L Strigari","year":"2010","unstructured":"Strigari L, Sciuto R, Rea S, et al. Efficacy and toxicity related to Treatment of Hepatocellular Carcinoma with 90Y-SIR spheres: Radiobiologic considerations. J Nucl Med. 2010;51(9):1377\u201385. https:\/\/doi.org\/10.2967\/jnumed.110.075861.","journal-title":"J Nucl Med"},{"issue":"7","key":"6813_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","volume":"34","author":"GM Knight","year":"2023","unstructured":"Knight GM, Gordon AC, Gates V, et al. Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2023;34(7):1214\u201325. https:\/\/doi.org\/10.1016\/j.jvir.2023.03.011.","journal-title":"J Vasc Interv Radiol"},{"key":"6813_CR19","unstructured":"American College of Radiology Committee on LI-RADS\u00ae (Liver). LI-RADS\u00ae v2018 CT\/MRI Manual. Accessed October 31. 2023. https:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/LI-RADS."},{"key":"6813_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"6813_CR21","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6813_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/life13061238","volume":"13","author":"SC Kappadath","year":"2023","unstructured":"Kappadath SC, Lopez BP. Single-compartment dose prescriptions for ablative 90Y-Radioembolization segmentectomy. Life (Basel). 2023;13(6):1238. https:\/\/doi.org\/10.3390\/life13061238.","journal-title":"Life (Basel)"},{"issue":"1","key":"6813_CR23","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1038\/s41598-021-82887-w","volume":"11","author":"MH Son","year":"2021","unstructured":"Son MH, Ha LN, Bang MH, et al. Diagnostic and prognostic value of 99mTc-MAA SPECT\/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image. Sci Rep. 2021;11(1):3207. https:\/\/doi.org\/10.1038\/s41598-021-82887-w.","journal-title":"Sci Rep"},{"issue":"2","key":"6813_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00270-014-1042-7","volume":"38","author":"MLJ Smits","year":"2015","unstructured":"Smits MLJ, Elschot M, Sze DY, et al. Radioembolization Dosimetry: the Road ahead. Cardiovasc Intervent Radiol. 2015;38(2):261\u20139. https:\/\/doi.org\/10.1007\/s00270-014-1042-7.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"6813_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00259-015-3157-8","volume":"43","author":"E Garin","year":"2016","unstructured":"Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of 99mTc-MAA SPECT\/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559. https:\/\/doi.org\/10.1007\/s00259-015-3157-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6813_CR26","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1007\/s00259-012-2189-6","volume":"39","author":"C Van de Wiele","year":"2012","unstructured":"Van de Wiele C, Maes A, Brugman E, et al. SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging. 2012;39(10):1646\u201355. https:\/\/doi.org\/10.1007\/s00259-012-2189-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6813_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","volume":"50","author":"N Kokabi","year":"2023","unstructured":"Kokabi N, Arndt-Webster L, Chen B, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023;50(6):1743\u201352. https:\/\/doi.org\/10.1007\/s00259-023-06111-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6813_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13550-022-00879-x","volume":"12","author":"EB Veenstra","year":"2022","unstructured":"Veenstra EB, Ruiter SJS, de Haas RJ, Bokkers RPH, de Jong KP, Noordzij W. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. EJNMMI Res. 2022;12(1):9. https:\/\/doi.org\/10.1186\/s13550-022-00879-x.","journal-title":"EJNMMI Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06813-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06813-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06813-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T01:29:02Z","timestamp":1727746142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06813-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6813"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06813-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was Institutional Review Board-approved in accordance with the Health Insurance Portability and Accountability Act by the University of San Diego Office of IRB Administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A waiver for written informed consent was provided as part of the Institutional Review Board approval based on the use of retrospective data alone.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No individual person\u2019s data in any form is included with this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Author ZTB has received speaking honoraria from Boston Scientific. The other authors disclose no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}